Search
lisdexamfetamine (Vyvanse)
dextroamphetamine bound to lysine (lisdexamfetamine mesylate) DEA class 2
Indications:
- attention deficit hyperactivity disorder (ADHD)
- binge eating disorder
- narcolepsy [2] (not FDA-approved use)
- augmentation of SSRI for depression somewhat effective [4]
- less so for SNRI [4]
Dosage: 30-70 mg QD
Pharmacokinetics:
1) inactive until lysine cleaved in the GI tract
2) inactive if injected or snorted
Interactions
drug adverse effects of ADHD medications
General
amphetamine (Mydayis)
References
- Prescriber's Letter 14(5): 2007
New Drug: Vyvanse (Lisdexamfetamine Dimesylate)
Detail-Document#: 230507
(subscription needed) http://www.prescribersletter.com
- Deprecated Reference
- FDA News Release. January 30, 2015
FDA expands uses of Vyvanse to treat binge-eating disorder.
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm432543.htm
- Giacobbe P, Rakita U, Lam R et al
Efficacy and tolerability of lisdexamfetamine as an antidepressant
augmentation strategy: A meta-analysis of randomized controlled
trials.
J Affect Disord. 2017 Oct 3;226:294-300. [Epub ahead of print]
PMID: 29028590
- Vyvanse Prescribing Information
http://pi.shirecontent.com/PI/PDFs/Vyvanse_USA_ENG.pdf